Home » Pipeline
Pipeline
February 2, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| ORIC Pharmaceuticals | ORIC-101 in combination with XTANDI (enzalutamide) | metastic prostate cancer | phase 1b trial dosing first patient |
| Syros Pharmaceuticals | SY-5609 | select solid tumors | phase 1 trial dosing first patient |
| Ikena Oncology | IK-175 (formerly KYN-175) | advanced solid tumors | phase 1 trial dosing first patient |
| Rubius Therapeutics | RTX-134 | phenylketonuria | phase 1b trial dosing first patient |
| Cerevel Therapeutics | CVL-936 | substance use disorder | phase 1 trial initiated |
| GlycoMimetics | GMI-1359 | advanced breast cancer | phase 1b trial dosing first patient |
| Epygenix Therapeutics | EPX-100 | Dravet Syndrome | phase 1 trial completed |
| Hansa Biopharma | imlifidase | Anti-GBM antibody disease | phase 2 investigator-initiated trial enrolling 15 patients |
| Anavex Life Sciences | ANAVEX 2-73 (blarcamesine) | Parkinson’s Disease | phase 2 trial enrolling 120 patients at 20 sites across Spain and three sites in Australia |
| Cassava Sciences | PTI-125 | Alzheimer’s Disease | phase 2b trial enrolling 64 patients |
| Isofol Medical | arfolitixorin | metastatic colorectal cancer | phase 1/2 trial completed |
| VistaGen Therapeutics | AV-101 oral NMDAR (N-methyl-D-aspartate receptor) | dyskinesia in patients with Parkinson's Disease receiving levodopa-based therapy | phase 2 IND cleared by the FDA |
| NuCana | Acelarin (NUC-1031) | biliary tract cancer | phase 3 trial dosing first patients in U.S. and Europe |
| Abbott | Infinity Deep Brain Stimulation system | Parkinson’s Disease | approved by the FDA for new indication |
| Epizyme | Tezverik (tazemetostat) | metastatic or locally advanced epithelioid sarcoma not eligible for complete resection | approved by the FDA |
| Merck | Dificid (fidaxomicin) | Clostridioides difficile-associated diarrhea in children ages six months and older | approved by the FDA |
| Teva Pharmaceuticals USA | AJOVY (fremanezumab-vfrm) autoinjector | migraine | approved by the FDA |
| Boehringer Ingelheim Eli Lilly |
Trijardy XR | type 2 diabetes | approved by the FDA |
| Pharmacosmos Therapeutics | Monoferric (ferric derisomaltose) injection | iron deficiency anemia | approved by the FDA |
